Markets:

Overview

News

Currencies

International

Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

32.57 -0.35 (-1.06%)

Streaming Delayed Price Updated: 1:53 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? ↗

March 31, 2026

.Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares are trading sharply higher Tuesday afternoon after the company said it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.

Via Benzinga

Why Agios Pharmaceuticals Stock Is Up More Than 21% Today ↗

March 31, 2026

The young drugmaker's sickle cell treatment is receiving special consideration from the United States' top drug regulator.

Via The Motley Fool

Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything ↗

March 31, 2026

Focused on therapies for rare blood disorders, this biotech saw a notable insider sale amid ongoing clinical development efforts.

Via The Motley Fool

Topics Regulatory Compliance

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

February 23, 2026

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss ↗

February 12, 2026

Via Chartmill

Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug ↗

November 20, 2025

Via Stocktwits

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Agios (AGIO) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Agios (AGIO) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter ↗

December 24, 2025

The stocks were tracked during the shortened Christmas Eve session across healthcare, consumer, and banking.

Via Stocktwits

Topics ETFs Economy Stocks

Here's Why Shares in Agios Pharmaceuticals Popped Today ↗

December 24, 2025

The company received FDA approval for its leading drug, and investors were pleased with the update from management.

Via The Motley Fool

Which stocks are gapping on Wednesday? ↗

December 24, 2025

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy

December 24, 2025

On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...

Via PredictStreet

Topics Economy

Why Did AGIO Stock Surge 14% Today? ↗

December 24, 2025

Agios Pharmaceuticals announced that the FDA approved its oral therapy for anemia in adults with alpha- or beta-thalassemia.

Via Stocktwits

Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗

December 24, 2025

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session.

Via Stocktwits

Topics ETFs Stocks

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 20, 2025

Via Benzinga

This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

November 20, 2025

Via Benzinga

Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 20, 2025

Via Benzinga

Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results

November 19, 2025

Boston, MA – November 19, 2025 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) experienced a dramatic and immediate market backlash, with its stock plummeting over 51.00% following the announcement of...

Via MarketMinute

Which stocks are moving on Wednesday? ↗

November 19, 2025

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Why Shares in Agios Pharmaceuticals Got Crushed Today ↗

November 19, 2025

The company's pivotal Phase 3 trial hit one primary endpoint but missed another.

Via The Motley Fool

Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗

November 19, 2025

Via Benzinga

Why Is Agios Pharmaceuticals Stock Sinking Today? ↗

November 19, 2025

Agios stock drops as mitapivat's Phase 3 trial shows strong hemoglobin gains but limited impact on sickle cell pain crises, prompting mixed investor reaction.

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

November 19, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Wednesday's session. ↗

November 19, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗

November 19, 2025

While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios...

Via Stocktwits

Wondering what's happening in today's pre-market session? ↗

November 19, 2025

Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 19, 2025

Via Benzinga

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tops Q3 2025 Estimates with Strong Revenue Beat ↗

October 30, 2025

Agios Pharma's Q3 2025 results beat revenue and EPS estimates, driving a positive market reaction and highlighting strong commercial performance.

Via Chartmill

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.